Pharmabcine Inc.

Lg Chem, Ltd

Eun Hee Lee

Weon Sup Lee

Sang Soon Byun

Miju Park

Seong Bae Kim

Jin-San Yoo

Woo Hyun Kim

Youngae Lee

Jinsang Yoo

Song Yi Yang

Byung Hyun Hwang

Sungho Ahn

Keunhee Oh

Hong Kyu Park

Sun Sik Shin

Hyuk Jin Lee

Seon Young Lee

Sung-Woo Kim

Do Yun Kim

Yi Rang Lim

Young Su Park

Do-Yun Kim

Sang Ryeol Shim

Jae Bong Yoon

Jin San Yoo

Seon Hwan Oh

Nam Ye Kim

Jong Geun Jeong

Jinhee Choi

Do-yun Kim

Ju Ryoung Nam

Mi Ae Jeon

Hyuk Joon Lee

Kyoung Hee Nahm

Boyoung Jeong

Jung Min Ha

Shin Ae Yi

Yeon Ju Kim

Ji Hye Jeong

Mi Ju Park

A positive electrode active material is provided, including a lithium transition metal oxide containing nickel (Ni), cobalt (Co), and manganese (Mn), wherein the lithium transition metal oxide has 60 mol % or more nickel (Ni) with respect the total number of moles of transition metal except lithium, and is doped with at least any one doping element selected from the group consisting of B, Zr, Mg, Ti, Sr, W, and Al. The positive electrode active material has an average particle diameter (D) of 4 μm to 10 μm after rolling at a rolling density of 3.0 g/cmto 3.3 g/cmand has the form of a single particle. A method of preparing the positive electrode active material, a positive electrode including the positive electrode active material, and a lithium secondary battery are also provided.

Positive electrode active material for lithium secondary battery and method of preparing the same

A positive electrode active material for a secondary battery includes a lithium composite transition metal oxide including nickel (Ni), cobalt (Co), and manganese (Mn), wherein the lithium composite transition metal oxide has a layered crystal structure of space group R3m, includes the nickel (Ni) in an amount of 60 mol % or less based on a total amount of transition metals, includes the cobalt (Co) in an amount greater than an amount of the manganese (Mn), and is composed of single particles.

Positive electrode active material including single particles of lithium nickel composite transition metal oxide, method of preparing the same, and lithium secondary battery including the same

Disclosed are an anti-PD-L1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for preventing or treating cancer containing the same, and a composition for co-administration with an antibody other than an antibody binding to PD-L1, containing the same.

Anti-PD-L1 antibody and use thereof

The present invention relates to an anti-VISTA antibody or an antigen binding fragment thereof, a nucleic acid coding for the same, a vector carrying the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or an antigen binding fragment thereof, a composition for prevention or treatment of autoimmune disease, comprising the same antibody, and a composition for concurrent administration in combination with a PD-1 antibody or PD-L1 antibody.

Anti-VISTA antibody and use thereof

Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.

Human antibody specific to c-Met and preparation method thereof

Growing community of inventors

Chungcheongnam-do, South Korea

Eun Hee Lee